SLC5A2 and metabolic dysfunction-associated steatotic liver disease: The sodium‐glucose cotransporter type 2 (SGLT2) inhibitors are a recently licensed class of antidiabetic agents that promote glucosuria through decreased renal glucose reabsorption, which in turn improves insulin sensitivity and glycemic control.11, 12 In addition, the EMPA‐REG study has demonstrated the positive impact that these agents may have on cardiovascular outcomes.13 SGLT2 inhibitors have been shown to be effective in several rodent models of NAFLD.